Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma

Development and Validation of a Quantitative Determination Method for the Antitubercular Drug PBTZ169 in Biological Media

(2018) E. S. Stepanova et al.   PHARMACEUTICAL CHEMISTRY JOURNAL

Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1

(2018) Adrian Richter et al.   Scientific Reports

Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect

(2017) Amedeo De Nicolò et al.   Bioanalysis

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

(2017) Kai Lv et al.   ACS Medicinal Chemistry Letters

New agents for the treatment of drug-resistant Mycobacterium tuberculosis

(2016) Daniel T. Hoagland et al.   ADVANCED DRUG DELIVERY REVIEWS

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

(2016) Robert S Wallis et al.   LANCET INFECTIOUS DISEASES

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis

(2015) Vadim Makarov et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis

(2015) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Biological Matrix Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing Biomonitoring

(2015) Parinya Panuwet et al.   CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY

Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS/MS

(2014) Caroline Bylda et al.   ANALYST

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

(2014) V. Makarov et al.   EMBO Molecular Medicine

Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans

(2013) Iñaki Comas et al.   NATURE GENETICS

Advances in the development of new tuberculosis drugs and treatment regimens

(2013) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Aspects of matrix effects in applications of liquid chromatography–mass spectrometry to forensic and clinical toxicology—a review

(2012) Frank T. Peters et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

In VitroCombination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis

(2012) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis

(2012) J. Neres et al.   Science Translational Medicine

Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl-β-d-ribofuranose 2′-Oxidase DprE1

(2011) Claudia Trefzer et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones

(2010) M. R. Pasca et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 ofMycobacterium tuberculosis

(2010) Claudia Trefzer et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE

Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP proposal

(2008) Ph. Hubert et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS